SCHEDULE: Kingdon Capital Reduces Jasper Therapeutics Stake Below 5%

Kingdon Capital Management and Mark Kingdon have filed an amended Schedule 13G, reporting a 4.7% beneficial ownership in Jasper Therapeutics, Inc.

Summary

• Kingdon Capital Management, L.L.C. and Mark Kingdon filed an Amendment No. 1 to Schedule 13G for Jasper Therapeutics, Inc.
• The filing reports beneficial ownership of 1,324,845 shares of Voting Common Stock, representing 4.7% of the class.
• This ownership percentage is below the 5% threshold, as indicated by Item 5 of the filing.
• The event requiring this filing occurred on September 30, 2025.
• Kingdon Capital Management, L.L.C. is classified as an investment adviser, and Mark Kingdon as a control person and individual.
• Both reporting persons share voting and dispositive power over all 1,324,845 shares.
• The securities are directly owned by advisory clients of Kingdon Capital Management, L.L.C., with no single client beneficially owning more than 5% of the Voting Common Stock.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, not a performance report or a statement of intent beyond passive investment, thus indicating a neutral sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership changes, specifically that Kingdon Capital Management's stake is now below the 5% threshold.

Key Dates

Keywords

Jasper Therapeutics, Kingdon Capital Management, Mark Kingdon, Schedule 13G, beneficial ownership, institutional ownership, common stock, equity stake, investment adviser